Skip to content

A clinical study on Sundiyathi chooranam in the management of Swasa kasam(Bronchial Asthma)

A Prospective open labelled, non-randomized, phaseII clinical trial on cuá¹?á¹­iyÄ?ti cÅ«raá¹?am in the management of cuvÄ?cakÄ?cam (Bronchial Asthma)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/05/025413
Enrollment
60
Registered
2020-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Sundiyathi Chooranam: 60mg/Kg/BW/Twice a day (orally) for 45 days Control Intervention1: Nil: Nil

Sponsors

Government Siddha Medical College and hospitall
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with the symptoms of dry cough, recurrent attacks of dyspnoea, hoarseness of voice, tightness of chest, profuse sweating and wheezing 2. History of allergens, climatic changes 3. Patients who are willing to take radiological investigations and provide blood for lab investigation

Exclusion criteria

Exclusion criteria: 1. Cardiac diseases 2. Chronic allergic bronchitis 3. Tuberculosis 4. COPD 5. Fibrosis 6. Restrictive airway disease 7. Status asthmaticus 8. Systemic Hypertension 9. Autoimmune diseases 10. Drugs and chemical 11. Renal disease 12. Pregnancy 13. Lactating mother

Design outcomes

Primary

MeasureTime frame
If during treatment/ after treatment reduction of the following symptoms 1. Tightness of chest 2. Hoarseness of voice 3. Profuse sweating 4. Wheezing 5. Dry cough 6. Recurrent attacks of dyspnoeaTimepoint: 45 days

Secondary

MeasureTime frame
1. To evaluate the pharmacological activities 2. Study about the prevalence of Swasa kasam in relation between diet and life styles 3. To determine about Antimicrobial activities in different solvents 4. To find out primary phytochemical analysis in trial drug 5. To evaluate spirometric changes in Swasa kasam 6. To evaluate safety profile for acute and subacute toxicity 7. To perform bio chemical analysisTimepoint: 45 days

Countries

India

Contacts

Public ContactDr T Komalavalli MD S Ph D

Government Siddha Medical College and Hospital

Komalaarumugam1@gmail.com9788122691

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026